Erratum: Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

被引：0
|
作者：
W Fiskus
S Sharma
B Shah
B P Portier
S G T Devaraj
K Liu
S P Iyer
D Bearss
K N Bhalla
机构：
来源：
Leukemia | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2014) 28, 2155–2164; doi:10.1038/leu.2014.119; published online 25 April 2014 Following the publication of this article, the authors noted that the loading control (β-actin) for the primary AML cells data presented in Figure 7b was incorrect. The correct western blot for theloading control (β-actin) has been added to Figure 7b.
引用
收藏
页码：1658 / 1658
相关论文
共 41 条
  • [1] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    W Fiskus
    S Sharma
    B Shah
    B P Portier
    S G T Devaraj
    K Liu
    S P Iyer
    D Bearss
    K N Bhalla
    Leukemia, 2014, 28 : 2155 - 2164
  • [2] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells
    Fiskus, W.
    Sharma, S.
    Shah, B.
    Portier, B. P.
    Devaraj, S. G. T.
    Liu, K.
    Iyer, S. P.
    Bearss, D.
    Bhalla, K. N.
    LEUKEMIA, 2014, 28 (11) : 2155 - 2164
  • [3] Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells (vol 28, pg 2155, 2014)
    Fiskus, W.
    Sharma, S.
    Shah, B.
    Portier, B. P.
    Devaraj, S. G. T.
    Liu, K.
    Iyer, S. P.
    Bearss, D.
    Bhalla, K. N.
    LEUKEMIA, 2017, 31 (07) : 1658 - 1658
  • [4] The histone demethylase LSD1/KDM1A as therapeutic target in AML
    Berg, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 272 - +
  • [5] Pre-Clinical Efficacy of Combined Therapy with LSD1 Antagonist SP-2509 and Pan-Histone Deacetylase Inhibitor Against AML Blast Progenitor Cells
    Fiskus, Warren
    Sharma, Sunil
    Abhyankar, Sunil
    McGuirk, Joseph
    Bearss, David J.
    Bhalla, Kapil
    BLOOD, 2012, 120 (21)
  • [6] Combined targeting of LSD1 (KDM1A) and histone deacetylases exerts superior efficacy against human AML
    Fiskus, Warren
    Sharma, Sunil
    Rao, Rekha
    Balusu, Ramesh
    Venkannagari, Sreedhar
    Ganguly, Siddhartha
    Bearss, David
    Bhalla, Kapil N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells
    Sonnemann, Juergen
    Zimmermann, Miriam
    Marx, Christian
    Ebert, Franziska
    Becker, Sabine
    Lauterjung, Marie-Luise
    Beck, James F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (03) : 494 - 497
  • [8] Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A
    Cuyas, Elisabet
    Gumuzio, Juan
    Lozano-Sanchez, Jesus
    Carreras, David
    Verdura, Sara
    Llorach-Pares, Laura
    Sanchez-Martinez, Melchor
    Selga, Elisabet
    Perez, Guillermo J.
    Scornik, Fabiana S.
    Brugada, Ramon
    Bosch-Barrera, Joaquim
    Segura-Carretero, Antonio
    Martin, Angel G.
    Antonio Encinar, Jose
    Menendez, Javier A.
    NUTRIENTS, 2019, 11 (07)
  • [9] Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human AML.
    Bhalla, Kapil N.
    Fiskus, Warren
    Peth, Karissa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Cytoplasmic translocation of nuclear LSD1 (KDM1A) in human hepatoma cells is induced by its inhibitors
    Yabuta, Suemi
    Shidoji, Yoshihiro
    HEPATIC ONCOLOGY, 2019, 6 (02)
12345